Dermatology Made Easy is based on the most popular topics from DermNet NZ's vast array of material. The book combines the essential focus of the ‘Made Easy’ book series with the authority and knowledge base of DermNet NZ's unparalleled resources.
Author: A/Prof Amanda Oakley, Dermatologist, Dept of Dermatology, Waikato Hospital, Hamilton, New Zealand, 2005.
What is basal cell naevus syndrome?
Basal cell naevus syndrome is a rare inherited condition characterised by:
Synonyms for basal cell naevus syndrome (BCNS) include basal cell carcinoma nevus syndrome (BCCNS), Gorlin-Goltz syndrome, Gorlin syndrome, and nevoid basal cell carcinoma syndrome. The so-called basal cell naevi are actually tiny basal cell carcinomas.
Developmental abnormalities in affected individuals may include:
Basal cell naevus syndrome is most often due to an abnormal PTCH 1 (patched) gene on chromosome 9q22.3-q31. This gene normally functions as a tumour suppressor so when it is not working properly it may allow cancers to grow. Other cases are due to mutations in 1p34.1 (PTCH 2 gene) or 10q24.32 (SUFU gene).
Basal cell naevus syndrome is an autosomal dominant condition meaning half of an affected person's children also have the syndrome. It affects one in every 50 to 100,000 people.
Recent research is studying how the genetics of basal cell carcinoma may lead to effective treatments in the future.
A diagnosis of basal cell naevus syndrome can be made if there are 2 major or 1 major and 2 minor criteria.
Basaloid follicular hamartoma has also been linked to a mutation in the patched gene but is a benign tumour. There are solitary and multiple hereditary variants.
The first sign of basal cell naevus syndrome may be the development of a medulloblastoma in a child aged 2 to 5 years, but luckily this is uncommon. Only a few children with medulloblastoma also have basal cell naevus syndrome. If detected early enough, the tumour may be treated by surgery and chemotherapy.
Patients with basal cell naevus syndrome often require surgery to remove jaw cysts in their 20s. Often, it is not until they are in their 30s or 40s that the basal cell carcinomas begin to appear so the diagnosis of the syndrome is often delayed.
All patients with basal cell naevus syndrome should see a dermatologist for regular skin examinations so that basal cell carcinomas can be treated when they are small. This may require surgery or one of the many other treatments available for these tumours including cryotherapy, photodynamic therapy, fluorouracil cream and imiquimod cream. They should not receive treatment with irradiation as this is liable to provoke the development of more tumours.
Sun protection is vital to reduce the number of skin cancers developing but even complete protection will not prevent all basal cell carcinomas in patients with basal cell naevus syndrome.
See the DermNet NZ bookstore
© 2018 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.